Radioactive treatment for advanced bladder cancer
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a new radioactive drug (177Lu-FAP-2286) for advanced bladder cancer that has stopped responding to standard treatments. The drug targets a protein on the cancer cells to deliver radiation directly to them, with the goal of shrinking tumors and controlling the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced bladder cancer that has not responded to standard treatments, or you can't have those treatments.
- You are 18 years or older.
- A special PET scan (FAPI scan) must show that your cancer has good uptake of the tracer, meaning the treatment is likely to work.
- Your blood counts (platelets, white blood cells, red blood cells) must be within acceptable levels.
- Your liver and kidney function must be normal or only slightly abnormal.
- You should be able to carry out your daily activities with little or no help (ECOG 0 or 1).
- You are expected to live at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special radioactive medicine (177Lu-CTR-FAPI) for people with advanced digestive cancers that have high FAP expression. The medicine targets a protein on cancer cells to deliver radiation directly to tumors, potentially slowing their growth.
This trial tests a new radioactive treatment (177Lu-OncoFAP-23) alone or combined with an immunotherapy (L19-IL2) for people with advanced solid tumors that have a specific protein called FAP. It's for patients whose cancer has grown despite standard therapies.
This trial tests how safe and effective a targeted radiation medicine (177Lu-FAP-2286) is for people with advanced solid cancers that have limited treatment options. It may help by delivering radiation directly to cancer-related targets and shrinking tumors.
This trial tests a new radioactive drug (225Ac-FAPI-XT) for people with advanced solid tumors that have stopped responding to standard treatments. It targets a protein called FAP found on many cancer cells, which may help deliver radiation directly to the tumor.
This trial tests a new drug that targets tumors with a specific marker you can see on a PET scan. It is for people whose cancer has spread or come back after standard treatments, and it may help shrink tumors or slow their growth.
This trial tests a new treatment that uses a radioactive medicine called [177Lu]Lu-RTX-2358 combined with immunotherapy (a type of drug that helps your immune system fight cancer). It is for people with advanced non-small cell lung cancer whose tumors have a specific marker called FAP.
Hear when a new Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.